Family history of venous thromboembolism in the paediatric population: The need for a standardized definition.


Journal

Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377

Informations de publication

Date de publication:
01 2019
Historique:
received: 30 09 2018
revised: 12 11 2018
accepted: 15 11 2018
pubmed: 1 12 2018
medline: 6 3 2019
entrez: 1 12 2018
Statut: ppublish

Résumé

Positive family history is known to be an independent risk factor for venous thromboembolic (VTE) that may or may not reflect an underlying hereditary disorder. However, there is no clear standardized definition of what constitutes a positive family history for VTE in children. We aimed to assess the current published definitions of positive family history as a risk factor for VTE in children and ascertain if any consensus exists. We conducted a literature review through two major databases PUBMED and EMBASE (1969-June 2018). Three different search statements were used for each database to maximize the number of relevant results, giving rise to 1050 non-duplicated papers. Of the 1050 papers, 32 articles demonstrated 18 separate definitions on what constitutes a positive family history in paediatric studies. Variations in definitions were related to the closeness of kinship (first or second-degree relatives), whether thrombosis was provoked or unprovoked, the age of presentation of thrombosis in the kinship, and clinical vs. laboratory definition of positive family history. Of the definitions, 1st degree relative/s developing VTE at any age whether provoked or unprovoked was most commonly described. According to this literature review, the definition of a positive family history in paediatric populations is non-standardized amongst current published papers. To enable accurate comparisons across studies and improve clinical risk assessment, we therefore propose the need for a standardized definition of what constitutes a positive family history.

Identifiants

pubmed: 30500675
pii: S0049-3848(18)30609-1
doi: 10.1016/j.thromres.2018.11.016
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

91-95

Informations de copyright

Copyright © 2018 Elsevier Ltd. All rights reserved.

Auteurs

Anna Hau (A)

John Hunter Children's Hospital, Newcastle, NSW, Australia. Electronic address: anna.hau@hnehealth.nsw.gov.au.

Eric Wegener (E)

Calvary Mater Hospital, Newcastle, NSW, Australia.

Vera Ignjatovic (V)

University of Melbourne, Melbourne, VIC, Australia; Murdoch Childrens Research Institute, Melbourne, VIC, Australia.

Shoshana Revel-Vilk (S)

Pediatric Hematology, Sharee Zedek Medical Center, Affiliated with Hadassah - Hebrew University Medical School, Jerusalem, Israel.

Paul Monagle (P)

Royal Children's Hospital, Melbourne, VIC, Australia; University of Melbourne, Melbourne, VIC, Australia; Murdoch Childrens Research Institute, Melbourne, VIC, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH